GFC Life Science

At a glance

GFC Life Science filed 76 disclosures in the last 12 months, including 25 5% holder, 20 insider and 2 buyback. The most recent key filing was on Oct 28: CEO bought 1,206 sh on the market at an average ₩4,594, Oct 26–28.

Revenue for 2025 was ₩17.7B, up 5.4% on 2024. Operating margin was 2.2% against 10.1% a year earlier. Debt was 42% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩10.5B and operating profit of ₩1B.

The 2025 annual report lists 86 employees with an average tenure of 4.3 years and average pay of ₩47.9M, #1547 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩100M each on average. It paid no cash dividend for 2025. 강희철 and related parties held 35.79% at year end.

Of 3 recent 5%+ holder reports, 3 raised and 0 cut a stake; the largest stake reported was 37.68% on Oct 28.

From the 2025 annual report

Staff: 86 (22 men, 64 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩3.3B. Directors and auditors: 6, paid ₩602M in total.

No cash dividend was paid for 2025.

Largest shareholder

강희철 holds 32.81%; with 5 related parties the group holds 35.79% of common shares at year end (from 42.66% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports